The below report was received by health authority ansm (reference number: (b)(4) on 18-mar-2024.This spontaneous case was originally reported by a consumer and describes the occurrence of back pain ("back pain") in a female patient who had essure inserted for female sterilisation.Additional non-serious events are detailed below.There was no information on the patient's medical history or concurrent conditions.On 08-nov-(b)(6) 2012, the patient had essure inserted.In 2017 she experienced tinnitus ("tinnitus since 2017").In (b)(6) 2021 she experienced back pain (seriousness criterion medically important).On unknown date she experienced eye irritation ("sensitive eyes (burning sensation)"), dizziness ("dizziness") and peripheral coldness ("cold extremities").At the time of the report, the outcomes for these events were unknown.No causality assessment was received for essure with regard to eye irritation, tinnitus, dizziness, peripheral coldness or back pain.The reporter commented: period of occurrence: 2017 and thereafter.Based on the available information, a review of our complaint records and other relevant data will be conducted; any new and reportable information that becomes available from our investigation will be provided in a supplementary report.
|
The below report was received by health authority ansm (reference number: (b)(4) on 18-mar-2024.The most recent information was received on 27-mar-2024.This spontaneous case was originally reported by a consumer and describes the occurrence of back pain ("back pain") in a female patient who had essure inserted for permanent contraceptive tubal implant.Additional non-serious events are detailed below.There was no information on the patient's medical history or concurrent conditions.On (b)(6) 2012, the patient had essure inserted.In 2017 she experienced tinnitus ("tinnitus since 2017").In (b)(6) 2021 she experienced back pain (seriousness criterion medically important).On unknown date she experienced eye irritation ("sensitive eyes (burning sensation)"), dizziness ("dizziness") and peripheral coldness ("cold extremities").At the time of the report, the outcomes for these events were unknown.No causality assessment was received for essure with regard to eye irritation, tinnitus, dizziness, peripheral coldness or back pain.The reporter commented: period of occurrence: 2017 and thereafter.Quality-safety evaluation of ptc: for essure: no defect could be confirmed by the manufacturer.All product batches have met the specifications regarding labeling, material, and process controls at time of release.Trend analyses of complaints are reviewed regularly, no signal was observed with regard to the reported complaint reason.The risk management file was reviewed and an update was not deemed required.A technical investigation of the complaint sample and batch record review could not be conducted, as no sample or batch number were available.The most recent follow-up information incorporated above includes data received on: 27-mar-2024: quality safety evaluation of product technical complaint.Based on the available information, a review of our complaint records and other relevant data was conducted; any new and reportable information that becomes available from our investigation will be provided in a supplementary report.
|